国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
11期
1287-1291
,共5页
拉米夫定%阿德福韦酯%恩替卡韦%疗效差异
拉米伕定%阿德福韋酯%恩替卡韋%療效差異
랍미부정%아덕복위지%은체잡위%료효차이
Lamivudine%Adefovir dipivoxil%Entecavir%Difference between clinical efficacy
目的 比较常用核苷类抗病毒药物疗效差异.方法 检索近3年核苷(酸)类似物拉米夫定、阿德福韦酯、恩替卡韦的临床药效报道,并进行分析.结果 不同报道中使用拉米夫定、阿德福韦酯、恩替卡韦治疗52(48)周的HBV-DNA阴转率分别为43.00%～85.00%、38.50%～94.00%和74.00%～87.50%;HBeAg血清转换率(或阴转率)为18.00%～35.50%、9.80%～43.60%和0～38.90%;ALT复常率为69.00%～94.70%、64.10%～100.0%和87.50%～91.00%.结论 拉米夫定、阿德福韦酯、恩替卡韦治疗慢性乙型肝炎疗效差异很大,需将药物与患者实际情况结合进行治疗.
目的 比較常用覈苷類抗病毒藥物療效差異.方法 檢索近3年覈苷(痠)類似物拉米伕定、阿德福韋酯、恩替卡韋的臨床藥效報道,併進行分析.結果 不同報道中使用拉米伕定、阿德福韋酯、恩替卡韋治療52(48)週的HBV-DNA陰轉率分彆為43.00%～85.00%、38.50%～94.00%和74.00%～87.50%;HBeAg血清轉換率(或陰轉率)為18.00%～35.50%、9.80%～43.60%和0～38.90%;ALT複常率為69.00%～94.70%、64.10%～100.0%和87.50%～91.00%.結論 拉米伕定、阿德福韋酯、恩替卡韋治療慢性乙型肝炎療效差異很大,需將藥物與患者實際情況結閤進行治療.
목적 비교상용핵감류항병독약물료효차이.방법 검색근3년핵감(산)유사물랍미부정、아덕복위지、은체잡위적림상약효보도,병진행분석.결과 불동보도중사용랍미부정、아덕복위지、은체잡위치료52(48)주적HBV-DNA음전솔분별위43.00%～85.00%、38.50%～94.00%화74.00%～87.50%;HBeAg혈청전환솔(혹음전솔)위18.00%～35.50%、9.80%～43.60%화0～38.90%;ALT복상솔위69.00%～94.70%、64.10%～100.0%화87.50%～91.00%.결론 랍미부정、아덕복위지、은체잡위치료만성을형간염료효차이흔대,수장약물여환자실제정황결합진행치료.
Objective Identify the difference in the use of Nucleoside analogues. Methods Search nearly 3-year clinical efficacy reports about nucleoside (acid) analogues like Lamivudine and Adefovir dipivoxil, Entecavir,and analyze the inner of the difference. Resaula In different reports, the effects of Nucleoside analogues bring a significant difference, including the HBV-DNA negative rate, Serum conversion rate of HBeAg, and Normalization rate of ALT. Conclusion When dealing with the Chronic Hepatitis B, Lamivudine and Adefovir dipivoxil, Entecavir have great different in effect, Doctor should take the actual situation in patients with the drug combination treatment.
